PATENT CLAIM ANALYSIS

Application Number: 16063047
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "001000"]

Abstract:
The existent therapeutic drugs for CNV are merely pharmaceuticals for a symptomatic therapy, and therapeutic drugs for radical cure are strongly demanded. Also, a therapeutic drug for Dry AMD does not exist, and therapeutic drugs for radical cure are strongly demanded. The present invention provides a prophylactic and/or therapeutic agent for choroidal neovascularization, containing a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient. Also, the present invention provides a drusen suppressor comprising a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient.

Claim (Index 8):
The drusen suppressor according to  claim 7 , wherein the nonsteroidal anti-inflammatory drug is at least one drug selected from the group consisting of zaltoprofen, oxaprozin, tiaprofenic acid, flufenamic acid, mefenamic acid, sulindac, ibuprofen, flurbiprofen, and pharmaceutically acceptable salts thereof,\n the aldose reductase inhibitor is epalrestat and/or a pharmaceutically acceptable salt thereof, the leukotriene receptor antagonist is at least one selected from the group consisting of zafirlukast, montelukast, pranlukast, and pharmaceutically acceptable salts thereof, the chemical mediator release suppressor is amlexanox and/or a pharmaceutically acceptable salt thereof, and/or, the thromboxane A2 receptor antagonist is seratrodast and/or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 41.0
- Percentile: 94.0
- Lexical Diversity: 2.0
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['12382702', '10685705', '13698518', '10773446', '14415994']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7888919105886527
- 35 USC 102 Novelty (BERT): 0.5272909858504177
- Combined Prediction Score: 0.7627318181148293
- Mean Citation Score: 307.786744
- Max Citation Score: 317.071
- Similarity Product: 210.2288603433967

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test